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Abstract
Resistance of Neisseria gonorrhoeae to expanded-spectrum cephalosporins such as ceftriaxone and 
cefixime has increased markedly in the past decade. The primary cephalosporin-resistance 
determinant is a mutated penA gene, which encodes the essential peptidoglycan transpeptidase, 
penicillin-binding protein 2 (PBP2). Decreased susceptibility and resistance can be conferred by 
mosaic penA alleles containing upwards of 60 amino acid changes relative to wild-type PBP2, or 
by non-mosaic alleles with relatively few mutations, the most important of which occurs at Ala501 
located near the active site of PBP2. Recently, fully cefixime- and ceftriaxone-resistant clinical 
isolates were identified that harbored a mosaic penA allele with an A501P mutation. To examine 
the potential of mutations at Ala501 to increase resistance to expanded-spectrum cephalosporins, 
we randomized codon-501 in a mosaic penA allele and transformed N. gonorrhoeae to increased 
cefixime resistance. Interestingly, only five substitutions of Ala501 (A501V, A501T, A501P, 
A501R, A501S) were isolated that increased resistance and preserved essential transpeptidase 
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function. To understand their structural implications, these mutations were introduced into the 
non-mosaic PBP2-6140CT, which contains four C-terminal mutations present in PBP2 from the 
penicillin-resistant strain FA6140. The crystal structure of PBP2-6140CT-A501T was solved and 
revealed ordering of a loop near the active site and a new hydrogen bond involving Thr501 that 
connects the loop and the SxxK conserved active-site motif. The structure suggests that increased 
rigidity in the active site region is a mechanism for cephalosporin resistance mediated by Ala501 
mutations in PBP2.
Graphical abstract
Neisseria gonorrhoeae is the causative agent of the sexually transmitted infection gonorrhea. 
Gonorrhea is the second most common bacterial sexually transmitted infection worldwide, 
with an estimated 78 million cases per year in 2012(1). Gonorrhea is mainly an infection of 
the lower urogenital tract, although it can also colonize the mucous membranes of the eyes, 
rectum and pharynx. If left untreated, infections in females can ascend to the upper genital 
tract and cause pelvic inflammatory disease and the associated increased risks of ectopic 
pregnancies and infertility. The efficacy of ceftriaxone, hitherto the most effective antibiotic 
against gonorrhea, is now being threatened by a large increase in infections over the past 
decade that are caused by cephalosporin intermediate-resistant strains (CephI), and most 
recently, by a small number of strains exhibiting high-level cephalosporin resistance 
(CephR). This has resulted in verified treatment failures with cefixime in many countries 
worldwide and sporadic treatment failures with ceftriaxone in Japan, Australia, Sweden, and 
Slovenia(2–4). The inexorable rise in ceftriaxone resistance portends a future with no 
effective antibiotics against gonococcal infections.
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N. gonorrhoeae undergoes natural transformation by importing DNA from the extracellular 
milieu and inserting it into its genome by homologous recombination. The extracellular 
DNA can come from other Neisserial species (including other strains of N. gonorrhoeae) 
that share the same host niche, and is the predominant means of acquiring resistance to 
antibiotics. The major determinant mediating resistance to cephalosporins is a mutated penA 
gene encoding penicillin-binding protein 2 (PBP2)(5). PBP2 is an essential peptidoglycan 
transpeptidase (TPase) involved in cell division, and the lethal target of β-lactam antibiotics 
used to treat gonorrhea. β-lactam antibiotics bind to PBPs and form a stable acyl-enzyme 
complex that inactivates the enzyme and prevents peptidoglycan cross-linking(6). The role of 
PBP2 in resistance was first noted in penicillin-resistant N. gonorrhoeae strains, which 
harbored a penA allele with both an Asp345a insertion and 4–8 mutations located within the 
carboxyl terminal domain(7). In the early 2000s, strains emerged in Japan and the Western 
Pacific Rim with much higher minimum inhibitory concentrations (MICs) of the expanded-
spectrum cephalosporins, ceftriaxone and cefixime, as well as of other oral cephalosporins 
that were in common use in Japan at that time(2, 5, 8). These strains contained so-called 
mosaic penA alleles with up to 60 amino acid mutations in the PBP2 coding sequence 
compared to a wild-type allele(5, 9). Strains harboring mosaic penA alleles often contain the 
mtrR and penB resistance determinants, which increase expression of the MtrCDE efflux 
pump and decrease diffusion of antibiotics across the outer membrane, respectively(10). The 
combination of these three determinants markedly increases resistance to ceftriaxone and 
cefixime(11, 12).
Mutations that confer decreased susceptibility to expanded-spectrum cephalosporins were 
also identified in non-mosaic mutant alleles of penA(13, 14). These mutations were mostly 
confined to a single amino acid, Ala501, which is located on the β3-β4 loop of PBP2. In 
particular, mutations of Ala501 to Val and Thr were associated with increased MICs of 
expanded-spectrum cephalosporins in non-mosaic alleles, but at the time had not been 
observed in mosaic penA alleles(13–15). In anticipation of Ala501 mutations appearing in 
mosaic penA alleles, we showed previously that introduction of an A501V mutation into the 
penA35 allele of the CephI strain 35/02 increased the MICs of ceftriaxone and cefixime by 
~3-fold. When introduced into FA6140, a penicillin-resistant but cephalosporin-susceptible 
strain that carries mtrR and penB mutations, the MIC increased to levels above the resistance 
breakpoint for the two antibiotics (MIC=0.25 μg ml−1 for both antibiotics)(16). Subsequently, 
we reported on a clinical isolate from France with a mosaic penA allele harboring an A501P 
mutation that conferred high-level resistance to cefixime and ceftriaxone. This same penA 
allele was reported in two isolates a year later in Spain(17, 18).
To understand the molecular mechanism of how mutations of Ala501 increase resistance, 
here we identified a set of six mutations that, when incorporated into mosaic and non-mosaic 
penA alleles, increased resistance to cephalosporins while retaining essential transpeptidase 
activity of PBP2. Structural analysis was initiated with the Ala501 mutants of the non-
mosaic PBP2 variant, PBP2-6140CT, and of these, PBP2-6140CT-A501T crystallized and 
was solved at 2.4 Å. The primary difference of this protein compared to PBP2-6140CT is 
that the mutation causes the β3-β4 loop to become ordered, whereas the same loop is 
disordered in both wild-type PBP2 and PBP2-6140CT. These data suggest that increased 
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rigidity of the β3-β4 loop is the primary mechanism by which these mutations confer 
resistance to expanded-spectrum cephalosporins.
Experimental Procedures
Strains and Plasmids
N. gonorrhoeae strain FA19, a penicillin- and cephalosporin-susceptible strain, was used for 
all transformations of mutant penA alleles. Gonococci were grown on GC Medium Base 
(GCB) agar plates containing Supplements I and II(19) at 37°C and 4% CO2 or in liquid 
GCB with Supplements I and II, 10 mM MgCl2, and 10 mM sodium bicarbonate in a 
shaking incubator. E. coli strain MC1061 was used for routine cloning experiments and was 
grown in Lysogeny Broth (LB) or on LB plates. Purified PCR amplification products for all 
penA mutants containing the 10 bp gonococcal uptake sequence(20) on one end of the 
fragment were used directly in transformation experiments.
Mutagenesis and Transformation
A library of penA35 mutants in which the codon for Ala501 was randomized was 
constructed by overlap-extension PCR(21). Briefly, the first fragment was amplified with a 
5′-primer complementary to codons 42–48 (and with the gonococcal uptake sequence 
GCCGTCTGAA at its 5′end) and a 3′-primer complementary to codons 495 to 500, three 
random bases, and codons 502–508. The second fragment was amplified with a 5′-primer 
comprising codons 502–508 and a 3′-primer that hybridizes ~200 bp downstream of the 
penA stop codon. A plasmid with penA35 cloned into pUC18us (pUC18 containing the 
gonococcal uptake sequence) was used as template. The resulting fragments were isolated, 
combined, and a second amplification was carried out with the 5′-primer of the first reaction 
and the 3′-primer from the second reaction. The resulting PCR product was sequenced to 
confirm randomization of codon 501, and then used to transform FA19 directly. Overlap-
extension mutagenesis with primers encoding A501G, A501K, A501L, and A501I mutations 
was used in later experiments to insert specific mutations of Ala501 into the penA35 allele.
Transformations were carried out exactly as previously described(16). Pilot experiments 
revealed that transformants of FA19 with penA35 could be selected at concentrations of 
cefixime between 0.02 and 0.08 μg ml−1, but decreased to nearly zero transformants at 
higher concentrations. Thus, FA19 bacteria transformed with the randomized PCR product 
were plated on GCB agar containing 0.1 μg ml−1 cefixime in the first set of experiments, and 
0.2 μg ml−1 cefixime in later experiments to identify alleles conferring the highest levels of 
resistance. Transformants with increased resistance were isolated, and bacteria were boiled 
in water to provide template for PCR reactions using the two outside primers from above. 
DNA fragments were purified with a PCR purification kit (Bio Basic, Amherst, NY) and 
sequenced (Genewiz, South Plainfield, NJ).
For the crystallization experiments described below, we introduced the five Ala501 
mutations identified in the randomized screen into PBP2-6140CT, which is a construct of 
PBP2 containing four mutations (relative to wild-type) in the C-terminal region that decrease 
the acylation rate of the protein with penicillin G by 5-fold(22). The same PCR protocol was 
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used as described above, except that primers with the specific codons were used in the PCR 
reactions.
MIC determinations, growth curves, and competitive co-culture
FA19 transformants harboring penA alleles with mutations at Ala501 were grown overnight 
on GCB plates, resuspended in GCB broth with supplements I and II, 10 mM MgCl2, and 20 
mM sodium bicarbonate at a final OD600 of 0.018 (~1 × 107 colony forming units (CFU) 
ml−1). Aliquots (5 μl) of each strain were spotted onto GCB plates containing antibiotics at 
<2-fold dilutions. The MIC was defined as the lowest concentration of antibiotic on which 
fewer than 5 colonies appeared after 24 hrs of incubation.
For assessment of growth kinetics, bacterial colonies with a non-piliated morphology were 
harvested from GCB agar plates after 18–20 hours incubation and inoculated into 35 ml of 
supplemented GC broth with 5 mM sodium bicarbonate at an initial optical density at 600 
nm (OD600) of 0.08. Bacteria were grown in untreated T75 tissue culture flasks for 8 hours 
shaking at 220 rpm and 37°C. The OD600 values were recorded every hour, and every two 
hours aliquots were removed for determination of viable bacteria (CFU ml−1). To avoid 
potential problems with clumping and to obtain more consistent CFU counts, bacteria were 
diluted in GCB + 0.05% saponin prior to plating.
For competitive co-culture experiments, similar numbers of FA19 bacteria and FA19 
bacteria harboring a penA35-A501 mutant allele were inoculated into GC broth as above 
and aliquots quantitatively cultured every two hours on non-selective GC agar (total number 
of CFU ml−1) and GC agar with either 0.016 μg ml−1 or 0.031 μg ml−1 of ceftriaxone for 
selection (number of mutant CFU ml−1). The higher ceftriaxone concentration was used to 
select for FA19 bacteria having an A501P or A501R mutation. The competitive index was 
determined at each time point, which is the ratio of mutant to wild-type bacteria divided by 
the ratio of mutant to wild-type bacteria in the initial inoculation. All growth experiments 
were repeated at least twice and gave similar results.
Acylation Rate Constants
The second order rate constants (k2/KS) of acylation with [14C]penicillin G (Moravek, Brea, 
CA) for PBP-35/02 with and without four Ala501 mutations (the A501S mutant was not 
assessed) were determined using purified protein, as described previously(22–24). The k2/KS 
values for ceftriaxone and cefixime were determined indirectly by determining the 
concentrations of the cephalosporins that inhibited the binding of [14C]penicillin G by 50% 
and using the following equation(24):
Protein purification and crystallization
The constructs encoding PBP2-6140CT with A501 mutations comprise residues 44–581 of 
PBP2 fused in-frame to the C-terminal end of His6-tagged maltose-binding protein (MBP) 
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with an intervening tobacco etch virus (TEV) protease site. The protein was expressed at 
18°C, the cells lysed, and the fusion protein was purified from the soluble fraction on a 
Ni2+-NTA column (GE Healthcare, Piscataway, NJ). The peak fractions were pooled and 
dialyzed at 4 °C at a 10:1 molar ratio of MBP-PBP2 to His6-TEV, which resulted in nearly 
complete digestion of the fusion protein. The mutant PBP2 variants were then rerun over a 
Ni2+-NTA column to remove His6-MBP, uncleaved fusion protein, and His6-TEV. The 
purified proteins were concentrated to ~20 mg ml−1 in 20 mM Tris•HCl, pH 8.0, 500 mM 
NaCl, 10% glycerol and stored at −80°C until ready for use.
Crystals of PBP2-6140CT-A501T were grown by vapor diffusion at 24°C in hanging drops, 
where the reservoir contained 2.2 M ammonium sulfate buffered with 100 mM Tris pH 8.25. 
Crystals were cryo-protected by passage through mother liquor to which glycerol had been 
added to a final concentration of 30% (v/v), followed by flash freezing in liquid nitrogen.
Data collection and refinement
Data were collected on the SER-CAT beam line ID22 in 1° oscillations, with a crystal-to-
plate distance of 200 mm and an exposure time of 3 sec at 40% transmission. Data were 
collected for 180° and processed using HKL2000(25). The space group and unit dimensions 
are the same as for wild-type PBP2(22) and there are two molecules in the asymmetric unit. 
The beginning model for refinement was the crystal structure of PBP2-6140CT (PDB code 
3EQV). The model was improved by iterative rounds of manual building using the program 
O(26) and REFMAC refinement(27). |Fo|-|Fc| difference maps were used to build the β3-β4 
loops that are ordered in this structure. The final model was refined to 2.4 Å and contains 39 
water molecules, 3 glycerols and 12 sulfates (Table 1). In both molecules of the asymmetric 
unit, positive electron density next to the side chain hydroxyl indicates that Thr465 is 
phosphorylated. This was also observed in both wild-type and 6140CT structures of PBP2 
and is presumed to be an artifact resulting from protein expression in the cytoplasm of E. 
coli(22).
Circular dichroism
PBP2, PBP2-6140CT and four PBP2-6140CT mutants (A501R, A501P, A501V, A501T) 
were each diluted to a concentration of 0.5–1 μM in a buffer containing 10 mM Tris-HCl, 
pH 8.0, 250 mM NaCl and 10% glycerol. Melting curves for each protein were measured in 
an AVIV Biomedical, Inc. (Lakewood, NJ) Model 400 circular dichroism (CD) 
spectrophotometer at 206 nm, which corresponds to the minimum in a 260 to 195 nm 
wavelength scan. Data were recorded every degree across the temperature range of 25 to 
75°C with 30 seconds of temperature equilibration time at each step. For each protein, at 
least 3 experiments were performed using a new sample each time and then averaged. All 
spectra were corrected against a control spectrum collected from buffer only. The molar 
ellipticity (ME) was calculated using AVIV software. The melting temperature (Tm) for each 
construct was calculated as the midpoint of the slope between the ME values where the 
protein was folded and unfolded.
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Results
Random selection of Ala501 mutants
To investigate the mechanism(s) by which mutations at Ala501 of PBP2 confer resistance to 
expanded-spectrum cephalosporins and to define the types of amino acids that confer 
increased resistance, we randomized codon-501 in the mosaic penA35 allele, transformed 
the library of randomized PCR products into the wild-type strain FA19, and selected for 
transformants with increased resistance to cefixime. We initially used 0.1 μg ml−1 cefixime 
for selection, and obtained hundreds of transformants with increased resistance; of these, we 
sequenced the penA genes from 65 strains (Table 2). Three mutations (A501R, A501V, and 
A501T) comprised 90% of the sequenced clones and were obtained with similar frequency, 
whereas two other mutations, A501S and A501P, were isolated at much lower frequencies. 
The identification of three of these mutations (A501V, A501T, and A501P) was expected, as 
these mutations have been observed in either non-mosaic penA alleles from strains with 
decreased susceptibility to cephalosporins (A501V and A501T)(13, 28–31), or in a mosaic 
penA allele from ceftriaxone-resistant strains (A501P)(17, 18). The isolation of just one 
A501P mutation in our screen was surprising given its prior emergence in the penA alleles 
of the ceftriaxone-resistant F89(17) and the Spanish gonococcal isolates(18). In contrast, the 
appearance of both A501R and A501S was novel, as these mutations have not yet been 
reported in a penA gene from any gonococcal clinical isolate.
To increase the probability of isolating transformants with Ala501 mutations that confer 
higher levels of resistance, we increased the stringency of selection by plating transformants 
at 0.2 μg ml−1 cefixime, which preliminary MIC data suggested would eliminate A501S, 
A501T, and A501V mutations, but select for A501R and A501P and any other mutations 
conferring higher levels of resistance. Under these selection conditions, only A501R 
mutations were obtained in 24 isolates sequenced (Table 2).
MICs of strains harboring penA35-A501 mutant alleles
The MICs of cefixime, ceftriaxone and penicillin G for FA19 strains containing the penA35 
allele with each of the five Ala501 mutations were determined (Fig. 1). For the 
cephalosporin MICs, these strains fell into two groups. The fold-increases in the MICs for 
FA19 penA35-A501V, -A501T, and -A501S relative to that of FA19 penA35 were very 
similar, with increases of 2- to 3-fold for cefixime and ~2-fold for ceftriaxone. In contrast, 
the MICs for FA19 penA35-A501R and -A501P were higher, with increases of ~5-fold for 
both antibiotics compared to that of FA19 penA35. These data are consistent with the 
increased resistance of strains such as F89 that harbor a mosaic penA allele with an A501P 
mutation(17), but also suggest that A501R mutations would be just as effective at increasing 
resistance if they appear in clinical isolates in the future. In contrast to the MICs of the 
extended-spectrum cephalosporins, the Ala501 mutations decreased the MIC of penicillin 
compared to the parental penA35 allele. Four of the mutants (A501S, A501T, A501V and 
A501R) conferred a 2-fold decrease in the MIC, while the A501P mutant conferred a 10-
fold decrease in the MIC.
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The isolation of only five mutations of Ala501 in the random screen suggested that only a 
small subset of mutations confers increased resistance to cefixime while retaining essential 
TPase activity. This result prompted us to investigate why other amino acids were not 
isolated in the screen. Two reasons seemed likely: 1) the mutant PBP2 proteins are 
functional as TPases but do not increase the MIC of cefixime to levels high enough to be 
selected above background, or 2) they are unable to catalyze sufficient levels of TPase 
activity. To distinguish between these possibilities, we generated four new Ala501 
mutations: A501I, A501L, A501K and A501G. Ile and Leu were chosen because they are 
most similar in size and hydrophobicity to Val, Lys because of its charge similarity to Arg, 
and Gly because of its smaller size relative to Ala.
FA19 was transformed with pUC18-penA35-A501I, -A501L, -A501K, or –A501G and 
resistant transformants were selected on 0.04 μg ml−1 cefixime, a concentration ~3-fold 
lower than the MIC of transformants harboring penA35 without Ala501 mutations, but high 
enough to ensure that FA19 did not grow. The transformations with penA35-A501L and -
A501G yielded no colonies, suggesting that these mutations disrupt essential TPase activity 
of PBP2. In contrast, transformants were obtained with penA35-A501I and –A501K, and 
subsequent PCR and sequencing verified that the mutations were present.
When the MICs of cefixime were determined, FA19 penA35-A501K was ~2-fold higher 
than FA19 penA35, similar to FA19 penA35-A501T, whereas FA19 penA35-A501I was 
essentially identical to FA19 penA35 (Fig. 2A). The inability of a penA35-A501I mutant 
allele to increase the MIC of cefixime above that conferred by penA35 is consistent with the 
absence of such transformants arising from the random screen. It was not evident, however, 
why A501K mutations were not identified in the screen. One consistent observation from 
these transformations was that while transformants of FA19 with penA35-A501K could be 
selected, the number of colonies obtained was markedly lower than that from 
transformations with other mosaic penA alleles.
To examine this phenomenon in more detail, we transformed FA19 with equivalent amounts 
of PCR products of six penA35-Ala501 mutants (penA35-A501T, -A501R, -A501I, -
A501K, -A501G, and -A501L) and quantified the number of resistant colonies obtained on 
plates containing 0.01 μg ml−1 cefixime, which is 10-fold lower than the MIC of FA19 
penA35 (Fig. 2B). Compared to penA35-A501T, the number of transformants with penA35-
A501R, -A501I and –A501P ranged from 45% to 15% of that obtained with penA35-A501T. 
In contrast, the transformation efficiency of penA35-A501K was 2.3% of penA35-A501T. 
Because the six DNAs differed at most by 3 nucleotides (i.e. the mutations at codon-501), 
our data suggest that the wide variation in the transformation efficiency of the different 
Ala501 mutants represents the viability of the transformant, and therefore most likely 
reflects the capacity of each PBP2 mutant to catalyze essential TPase activity. This is an 
important factor when considering the likelihood that these mutations will emerge in mosaic 
penA alleles in nature.
In previous work, we have shown that some mutations, while critical for increasing 
resistance to β-lactam antibiotics, require other mutations (called epistatic mutations) that 
allow the critical mutations to increase resistance(16). We therefore asked whether a single 
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A501P mutation in the wild-type penA background could confer an increase in the MIC of 
cefixime. FA19 was transformed with penA-A501P and sequence-verified transformants 
could be obtained at 0.01 μg/ml cefixime (4-fold higher than its MIC for FA19). Consistent 
with our MIC data for penicillin G (Fig. 1), no transformants of FA19 penA-A501P were 
obtained when selected on a concentration of penicillin G 2-fold higher than the MIC for 
FA19. These data indicate that the A501P mutation is capable of conferring cefixime 
resistance without any additional mutations present in the penA35 allele.
Acylation rate constants of mutant PBPs
We next assessed the in vitro acylation rates for cefixime, ceftriaxone, and penicillin G. 
These 2nd order rate constants (defined as k2/KS) describe both the acylation rate constant 
(k2) and the binding affinity of the antibiotic (KS)(24). As shown in Table 3, the k2/KS 
constants of the PBP2-35/02-Ala501 mutants identified in the screen were mostly consistent 
with the MICs of strains containing these variants, with the exception of the rate constants of 
ceftriaxone, which actually increased in the A501T and A501V mutant constructs compared 
to PBP-35/02. Consistent with the decreased MICs of penicillin G for FA19 harboring the 
Ala501 mutants (Fig. 1), the k2/KS values for all of the PBP2 variants were higher than that 
for PBP235/02. However, the k2/KS values and the MIC did not show a linear or proportional 
correlation. For example, the k2/KS values for penicillin G of PBP235/02-A501R and –
A501P were very similar and ~1.5- to 2-fold lower than the –A501V and -A501T variants, 
but while FA19 penA35-A501R had a 2-fold lower MIC than FA19 penA35, FA19 penA35-
A501P had a 10-fold lower MIC. Likewise, the k2/KS values of PBP235/02-A501P for 
ceftriaxone and cefixime were ~20-fold lower than PBP235/02-A501R, but the MICs of the 
two antibiotics for FA19 harboring the different alleles were about the same. As discussed 
later, these data suggest that, in addition to rates of acylation, other factors can influence the 
MIC.
Effects of Ala501 mutations on bacterial fitness
Antibiotic-resistance determinants, especially those that are altered versions of an essential 
enzyme, can decrease growth and/or fitness of the bacteria(32). To assess the fitness cost of 
the Ala501 mutations in the penA35 background, we measured the in vitro growth rate of 
strains cultured alone or in competition with the parental strain, FA19. The presence of the 
mutant penA35 allele either with or without Ala501 mutations negatively impacted growth 
of the bacteria compared to FA19, causing a shorter logarithmic phase as measured by 
OD600 and a decrease in the number of viable bacteria (CFU ml−1) recovered over time (Fig. 
3A, B). When measured in co-culture experiments, all of the resistant strains were out-
competed by FA19, with FA19 penA35-A501R and FA19 penA35-A501P showing the 
smallest competitive index (Fig. 3C). These data indicate that the penA35 allele itself 
negatively impacts growth of a wild-type strain, particularly at later time points, and that 
mutation of Ala501 to Arg or Pro, but not Val, Thr, or Ser, further impacts growth.
Effects of Ala501 mutations in a non-mosaic PBP2 background
We next incorporated the Ala501 mutations into PBP2-6140CT (PBP2 containing the four 
point mutations, but not the Asp346a insertion, found in PBP2 from FA6140;(22)) for 
structural studies. This was done for several reasons: 1) we had already solved the structure 
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of PBP2-6140CT, which increased the probability of obtaining crystals in this background 
compared to the PBP235/02 background (as yet, PBP235/02 constructs have not crystallized); 
2) Ala501 mutants originally emerged in non-mosaic alleles of penA, making this 
background clinically relevant(13–15); and 3) interpretation of the effects of the Ala501 
mutations would be much less complicated in a non-mosaic PBP2 background.
To ascertain the effects of the Ala501 mutations in a non-mosaic background, we determined 
the MICs of cefixime and ceftriaxone of FA19 penA-6140CT alone or with one of four 
Ala501 mutations (Fig. 4). Unlike with penicillin G, the mutations in PBP2-6140CT have no 
effect on the MICs of cefixime or ceftriaxone. Incorporation of the A501V mutation into 
PBP2-6140CT conferred a ~2-fold increase in the MIC, whereas incorporation of A501T or 
A501R increased the MIC ~3-fold. In contrast, incorporation of an A501P mutation into 
PBP2-6140CT increased the MICs of cefixime and ceftriaxone by 14- and 9-fold, 
respectively.
Crystal structure description of PBP-6140CT-A501T
The PBP2-6140CT variant containing an A501T mutation crystallized under similar 
conditions as PBP2 and PBP2-6140CT with two molecules in the asymmetric unit and the 
structure was solved to 2.4 Å resolution (none of the other PBP2 variants yielded crystals 
that diffracted to high resolution). Inspection of |Fo|-|Fc| difference electron density maps 
revealed that the β3-β4 loops of both molecules in the asymmetric unit could be modeled. 
This is in marked contrast to the structures of PBP2 and PBP2-6140CT, in which residues 
501–512 lacked electron density in both molecules of the asymmetric unit. Although the 
electron density for the side chains in this loop is comparatively weak in places, especially at 
its apex, that for the main chain is mostly complete, thus establishing the overall structure of 
the loop.
Two observations suggest that the ordering of the β3-β4 loop is a direct consequence of the 
A501T mutation and not crystal packing interactions. Firstly, being of the same crystal form, 
the A501T mutant of PBP2-6140CT has the same packing arrangement as the wild-type 
structure. Secondly, the structures of the β3-β4 loops in both molecules of the asymmetric 
unit of PBP2-6140CT-A501T are very similar and yet each has different packing 
environments. In molecule B, the β3-β4 loop packs against the β2a-β2b loop of a 
neighboring molecule and against β7n of the N terminal region of another neighboring 
molecule, whereas the β3-β4 loop of molecule A is exposed to solvent.
The structures of wild-type PBP2 and PBP2-6140CT-A501T superimpose very closely, with 
an RMS deviation between all common main chain atoms of 0.30 Å for molecule A and 0.36 
Å for molecule B. The only significant difference between the structures is the ordering of 
the β3-β4 loop in the A501T mutant (Fig. 5). Since PBP2 and PBP2-6140CT have 
essentially the same structures, a superimposition of the A501T mutant with PBP2-6140CT 
produces the same outcome.
Thr501 forms a hydrogen bond near Ser310
The site of the mutation is at the end of β3, where its threonine side chain packs closely 
between Val515 on β4 and Tyr422 at the C-terminal end of α8. A further consequence of the 
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A501T mutation is that the side-chain hydroxyl of Thr501 is within hydrogen bonding 
distance of the main-chain carbonyl of Glu307, thus forming a new connection between β3 
and the loop immediately prior to Ser310 (Fig. 6). The nearly exact overlap of wild-type and 
A501T mutant structures of PBP2 in this region shows that the new hydrogen bond does not 
alter the architecture, but it may nevertheless be close enough to impact nucleophilic 
activation of Ser310.
Thermal stability of 501 mutants
The ordering of the β3-β4 loop of PBP2 in the PBP2-6140CT-A501T structure suggests a 
mechanism of antibiotic resistance involving increased rigidity of the protein. To evaluate 
the impact of the mutations at position 501 on the stability of the protein, we collected 
irreversible thermal denaturation curves for the Thr, Val, Pro and Arg mutants of 
PBP2-6140CT using circular dichroism (CD) spectroscopy. Spectra were also recorded for 
wild-type PBP2 and for PBP2-6140CT. Surprisingly, the Tm of all the mutants was 
significantly lower than that of wild-type PBP2, suggesting an overall destabilizing effect of 
the mutations (Fig. 7). Furthermore, all of the Ala501 mutants exhibit a lower Tm than 
PBP2-6140CT, with A501R and A501P mutations lowering Tm the most. The contrast 
between observed ordering of the β3-β4 loop and lowered thermal stability of the mutant 
proteins is discussed below.
Discussion
In this study, we identified five amino acids (Thr, Val, Ser, Arg, and Pro) in a random screen 
for mutations at Ala501 of PBP2, plus an additional amino acid (Lys) by site-directed 
mutagenesis, that increase resistance of N. gonorrhoeae to expanded-spectrum 
cephalosporins over that conferred by the parental mosaic PBP, PBP2-35/02. Three of these 
amino acids, Thr, Val, and Pro, have been identified previously as mutations at Ala501 in 
penA alleles from gonococcal clinical isolates, while Ser, Arg and Lys have not. Of these, 
both A501R and A501P mutations have a more pronounced effect on the MIC (~5-fold) and 
appear to cause a larger fitness deficit compared to the other mutations. The structure of 
PBP2-6140CT-A501T reveals that the primary impact of the A501T mutation is to promote 
ordering of the β3-β4 loop.
Antibiotic resistance determinants often have a negative effect on fitness. This is particularly 
true with mosaic PBP2 variants as these likely have sub-optimal TPase activity. 
Unfortunately, in the absence of a biochemical assay of TPase activity using purified PBPs 
(particularly for the class B PBPs such as PBP2)(6), it is not possible to quantify directly the 
impact of resistance mutations on the TPase function of PBP2. That said, our in vitro growth 
experiments suggest that bacteria expressing a mosaic penA allele (penA35) grow less well 
than wild-type bacteria. Moreover, the two Ala501 mutations that increase the MICs of 
cefixime and ceftriaxone the most (i.e. A501P and A501R) are the least fit in competitive 
co-culture experiments, which would be expected if these mutations have a more deleterious 
effect on TPase activity than the other mutations. It seems likely, therefore, that 
dissemination of any of these alleles containing Ala501 mutations would require 
compensatory mutations in the strain that increase fitness. Indeed, compensatory mutations 
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that help abrogate the fitness defect of resistance alleles have been identified in other 
bacteria, and for an mtrA mutant and an mtrR/gyrA/parC triple mutant in N. 
gonorrhoeae(33, 34).
Surprisingly, nearly 50% of the total transformants sequenced in the random screen harbored 
an A501R mutation, compared to the identification of a single transformant containing an 
A501P mutation. The high number of transformants obtained containing A501R mutations 
compared to A501P mutations was particularly unexpected, because in the clinical setting, 
three temporally and geographically distinct cefixime-resistant isolates harbored a mosaic 
penA allele with an A501P mutation(17, 18), but no isolates with an A501R mutation have 
been observed to date. We investigated this apparent anomaly by comparing the 
transformation frequencies of identical quantities of penA35 PCR fragments containing 
different mutations at Ala501, and observed large differences in the capacities of these 
DNAs to transform competent gonococci. One explanation for these differences is that they 
reflect the degree to which transpeptidase activity is compromised by the mutation, although 
this does not explain why only A501P mutations have occurred in nature. Irrespective, these 
results highlight the fine line that N. gonorrhoeae must navigate to increase resistance to 
antibiotics by remodeling PBP2 whilst preserving essential TPase activity.
An interesting observation from these studies is that there is not a clear correlation between 
the acylation rates of purified proteins and the MICs of β-lactam antibiotics for FA19 
harboring the corresponding penA alleles. The MIC of a β-lactam antibiotic for N. 
gonorrhoeae is determined by three main characteristics: i) the acylation rate of PBP2, ii) the 
capacity to serve as a substrate for efflux pumps, and iii) the rate of influx through porin 
channels. An additional factor is the degree to which the PBP2 variant needs to be inhibited 
to cause cell death. For example, the TPase activity of wt PBP2 may need to be inhibited by 
80–90% to cause cell death, whereas that of the PBP235/02-A501P variant, which our data 
suggest is markedly impaired, may only need to be inhibited by 30–40% before the level 
falls below the threshold that supports cell growth. The lack of correlation observed in this 
study between the acylation rates and MICs of the different antibiotics is most evident for 
the A501P mutant, and is consistent with the fitness data and transformation frequencies.
We crystallized PBP2-6140CT containing the A501T mutation and solved its structure to 2.4 
Å. The most striking difference compared to the crystal structure of PBP2-6140CT is 
significant ordering of the β3-β4 loop. This same loop in other PBPs has also been 
associated with resistance to β-lactams. A Q556E mutation in Streptococcus pneumoniae 
PBP2x, which is implicated in cephalosporin resistance, lies in a very similar position as 
Ala501 at the C-terminal end of β3(35). Similarly, for S. pneumoniae PBP1a, there is a 
clustering of four mutations on the β3-β4 loop that lowers the rates of acylation for 
cefotaxime and penicillin G(36). Interestingly, whether the β3-β4 loop is ordered or 
disordered varies in relation to resistance. In the crystal structure of PBP1a from the R6 
(susceptible) strain of S. pneumoniae, the β3-β4 loop is ordered, but is disordered in the 
protein derived from the cephalosporin-resistant strain 5204(37). Opposite to that and in 
alignment with N. gonorrhoeae PBP2, the crystal structure of PBP2a from S. pneumoniae 
shows a disordered β3-β4 loop in the protein derived from the susceptible strain and an 
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ordered loop in the protein from the resistant strain(38). These observations have led to the 
idea that flexibility in this region is a key factor in antibiotic resistance(38).
A key question is how mutations at position 501 confer increased resistance to 
cephalosporins. One simple mechanism is that larger side chains at position 501 sterically 
impede the binding of antibiotic. Given the close proximity of position 501 to the core of the 
active site, direct clashes between side chains at position 501 and the cephalosporin can be 
envisaged (see Fig. 5). These clashes would block binding of antibiotic (i.e. increase KS) and 
thereby lower the rate of acylation, while in some way retaining the capacity to recognize 
the peptide C-terminus of peptidoglycan during transpeptidation. In a similar vein, the 
negative charge introduced by the Q552E mutation in S. pneumoniae PBP2x is believed to 
impede binding of antibiotic in a direct manner(35). This mechanism is consistent with the 
mutations all introducing larger side chains at position 501 and the proportionally higher 
increase of MICs for the largest side chain, Arg. It does not explain, however, why mutation 
of Ala501 to Ile, which also introduces a larger side chain, has no effect on resistance, 
suggesting that steric hindrance alone does not explain the changes in resistance in PBP2.
Perhaps the most compelling mechanism, and consistent with changes in the crystal 
structure, is that resistance results from increased rigidity of the active site and its immediate 
environs. As revealed by the structure of PBP2-6140CT-A501T, the β3-β4 loop exhibits 
significantly increased order, compared to the otherwise identical protein construct lacking 
the A501T mutation. One possible reason for this is the new hydrogen bond between Thr501 
and Glu307 near the SxxK motif that tethers the beginning of β3 with a loop preceding the 
SxxK motif. The other mutations at position 501 also have the potential to lower flexibility. 
A serine would likely form the same hydrogen bond with Glu307 as threonine. A valine 
cannot mediate a hydrogen bond, but could form hydrophobic interactions with Val515 and 
Tyr422. An arginine could form a new electrostatic interaction with the side chain of Glu307 
and introduction of proline would clearly restrict conformational freedom.
At first sight, the idea of increased rigidity causing resistance to cephalosporins appears at 
odds with the circular dichroism results. These data show that mutations at Ala501 lower the 
thermal stability of the protein and thus appear more consistent with a mechanism in which 
resistance mutations destabilize the enzyme. However, the apparent destabilization of the 
protein detected by a lowered Tm may result from entropic compensation elsewhere in the 
protein framework. This situation has been described as a rigidity-flexibility equilibrium, 
where lowered entropy due to a stabilizing mutation at one site is compensated by increased 
flexibility in remote regions(39). The reverse can also happen when the mutation is 
destabilizing. Relationships between mutations, protein stability and ligand binding are 
generally protein specific and specific mutations can reduce ligand affinity by lowering or 
increasing the stability of proteins(40). In the case of PBP2, it appears that mutations at 
position 501 reduce reactivity for β-lactams via increasing localized ordering in the active 
site region and the entropic penalty is paid by increased flexibility elsewhere in the 
framework that is detected by circular dichroism.
Increased rigidity in the active site could lower rates of acylation by cephalosporins in two 
ways: by preventing requisite conformational changes necessary for binding of the 
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antibiotic, or by hindering formation of the ideal geometry of the transition state for 
acylation (i.e. by lowering k2). The first of these mechanisms infers that binding of 
cephalosporins by PBP2 requires movement of the protein to bind the antibiotic in a 
productive orientation prior to acylation. Due to the increased rigidity conferred by the 
mutations at position 501, the energetic barrier against such conformational changes is made 
higher and thus cephalosporins are less likely to acylate the enzyme successfully. This 
mechanism may act synergistically with the simple steric hindrance described above. A 
similar mechanism was proposed for S. aureus PBP2a in which mutations associated with β-
lactam resistance were hypothesized to restrict movement of β3(41).
The second mechanism is derived from the mechanistic relationship between PBPs and 
serine proteases. It is well established that acylation requires the formation of a tetrahedral 
intermediate in which the negative charge of the intermediate is stabilized by an oxyanion 
hole, which in PBP2 comprises the amide nitrogens of Ser310 and Thr500. The latter, of 
course, is immediately adjacent to Ala501. A productive transition state requires precise 
geometry, and increased rigidity in the structure elicited by mutations at position 501 may 
create a barrier to successfully achieving this state with the kinetic consequence of lowered 
rates of acylation.
Of course, in both of these mechanisms, the peptidoglycan substrate of PBP2 must be less 
affected than antibiotic, and how this is achieved is a matter of significant interest. One 
possibility is that the larger peptide substrate overcomes the energetic barrier imposed by the 
Ala501 mutations by making more contacts with the enzyme. That said, it seems inevitable 
that the efficiency by which the acyl-enzyme complex forms with peptide substrates must be 
compromised to some degree, and this is consistent with the larger fitness deficit of bacteria 
harboring penA alleles with Ala501 mutations that increase the MIC the most (Arg and Pro), 
as revealed in the competitive co-culture experiments.
The opposite effect of the A501P mutation on penicillin G MICs and k2/KS compared to 
cefixime and ceftriaxone is interesting because the mechanisms that discriminate against 
cephalosporins must somehow favor reactivity with penicillin. How this happens 
mechanistically is unclear, but perhaps the precise active-site geometry that is formed by this 
mutation is ideal for the binding or acylation of penicillin G. There are key chemical 
differences between cephalosporins and penicillins that can affect binding and/or reactivity 
with a PBP, including the 6-membered dihydrothiazine ring of cephalosporins rather than 5-
membered thiazolidine ring of penicillins, the presence of a C3 substituent in 
cephalosporins, and the different groups comprising the R1 side chains.
In this study, we have shown that specific mutations of Ala501 in PBP2 can cause 
cephalosporin resistance in N. gonorrhoeae while retaining sufficient essential 
transpeptidase function necessary for viability. Substitutions to amino acids with 
significantly different physicochemical properties compared to Ala confer the biggest 
increases on MICs. A crystal structure of PBP2 containing an A501T mutation shows 
dramatic ordering of the β3-β4 loop and suggests that increased rigidity in the active site 
correlates with resistance. These results are important for predicting future emergence of 
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Ala501 mutations that may threaten the clinical utility of cephalosporins against gonorrhea 
and for understanding the underlying molecular mechanism of resistance.
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Abbreviations and Textual Footnotes
PBP Penicillin-Binding Protein
TPase transpeptidase
MIC minimum inhibitory concentration
CephI cephalosporin-intermediate resistant
CephR cephalosporin-resistant
GCB GC Medium Base
LB lysogeny broth
CFU colony forming units
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Figure 1. MICs of cefixime, ceftriaxone, and penicillin G for Neisseria gonorrhoeae strain FA19 
harboring penA35-Ala501 mutants
Strains were generated by transformation with the indicated penA allele, and the MICs of 
the indicated antibiotics were determined as described in Material and Methods. The MICs 
reported are the averages ± standard deviation determined from a minimum of 3 independent 
experiments using 3–6 sequence-verified transformants of each strain.
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Figure 2. MICs and relative transformation efficiencies of Neisseria gonorrhoeae strain FA19 
harboring penA35-Ala501 mutants
A, MICs of cefixime for the indicated strains; the data were generated and graphed as 
described in the legend to Fig. 1. B, Normalized transformation frequencies of the indicated 
penA35-A501 variants. Equal amounts of DNA were used to transform FA19, and 
transformants were selected on 0.01 μg ml−1 of cefixime. For each experiment, the relative 
transformation frequency for each strain was determined as a ratio of that obtained with 
penA35-A501T. The experiment was repeated three times and the ratios were averaged ± 
standard deviation.
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Figure 3. In vitro fitness of Neisseria gonorrhoeae strain FA19 harboring penA35-Ala501 mutant 
alleles
Growth of FA19 harboring wild-type penA, the mosaic penA35, or penA35-Ala501 mutant 
alleles cultured individually was monitored in liquid GCB medium by quantifying the 
OD600 (A) and number of colony-forming units (CFU) per ml (B). C, Competitive co-
cultures of FA19 versus either FA19 penA35 or individual FA9 penA35-Ala501 mutants. 
Results are expressed as a Competitive Index (CI) as described in Materials and Methods. 
CIs less than 1 indicate reduced fitness relative to parent FA19. The experiments were 
repeated twice with similar results (results from a single experiment are shown).
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Figure 4. MICs of cefixime and ceftriaxone for FA19 alone or FA19 harboring penA6140CT-
Ala501 mutant alleles
The MICs were determined by agar dilution as described in Materials and Methods and 
represent the averages (± standard deviation) determined from a minimum of 3 independent 
experiments using 3–6 sequence-verified transformants of each strain.
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Figure 5. The β3-β4 loop is ordered in the PBP2 A501T mutant
Superimposition of molecule A of wild-type PBP 2 (3EQU; slate blue) with molecule A of 
PBP2-6140CT-A501T (orange). Cefuroxime has been docked into the wild-type structure 
based on the structure of the acylated PBP2x from S. pneumoniae (1QMF). Active site 
residues of the SxxK, SxN, and KTG motifs are shown in stick form.
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Figure 6. Close-up view of the PBP2 region near the A501T mutation
Superimposition of molecule B of wild-type PBP2 (3EQU; blue) and molecule B of 
PBP2-6140CT-A501T (orange). Cefuroxime has been docked into the wild-type structure 
based on the structure of the acylated PBP2x from S. pneumoniae (1QMF).
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Figure 7. Melting temperatures of PBP2, PBP2-6140CT, and PBP2-6140CT-A501 mutants
The increase in molar ellipticity at 208 nm of the indicated PBP variants was quantified at 
different temperatures by circular dichroism.
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Table 1
X-ray diffraction data and refinement statistics
Rmerge=Σ|Ii − Im |/ΣIi, where Ii is the intensity of the measured reflection, and Im is the mean intensity for all 
observations of that reflection. Numbers within parentheses are for the outer resolution shell of data.
Data collection:
 Cell dimensions: a, b, c (Å) 57.6, 137.2, 229.8
 Resolution range (Å) 39.0 – 2.40 (2.44–2.40)
 Rmerge* (%) 10.7 (99.8)
 Completeness (%) 98.9 (97.6)
 Redundancy 5.9 (5.5)
 <I>/<σI> 26.0 (2.5)
 No. of unique reflections 71,874 (3,435)
Refinement:
 Resolution (Å) 39.0 – 2.4
 No. of sulfates 12
 No. of glycerols 3
 No. of water molecules 39
 Rcryst/Rfree (%) 0.218/0.244
 RMS deviations from ideal stereochemistry:-
  bond lengths (Å) 0.013
  bond angles (°) 1.72
 Ramachandran plot:
  Residues in most favored region (%) 92.2
  Residues in disallowed region (%) 7.8
  Residues in generously allowed regions 0.0
  Residues in disallowed regions 0.0
 PDB code 5KSH
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Table 2
Random mutagenesis of Ala501 in PBP2 revealed 5 amino acids that increase resistance to 
expanded-spectrum cephalosporins
Transformants were selected at the indicated concentrations of cefixime, and the penA genes were amplified 
and sequenced. Data are from three independent transformations.
Cefixime concentration used for selection Ala501 mutations Number of isolates
0.1 μg ml−1
Arg 21
Ser 5
Thr 20
Val 18
Pro 1
0.2 μg ml−1 Arg 24
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Table 3
k2/Ks second order rate constants for acylation
The values represent the mean ± standard deviation for 3 independent determinations.
PBP2 Variant
k2/KS (M−1s−1)
Cefixime Ceftriaxone Penicillin G
PBP2 1480000 ± 22000  1710000 ± 90000 75700 ± 2300
PBP235/02 7170 ± 280 11300 ± 440 510 ± 90
PBP235/02-A501T 5550 ± 160 30400 ± 300 1860 ± 130
PBP235/02-A501V 3150 ± 120 20000 ± 390 1370 ± 140
PBP235/02-A501R 820 ± 40 6460 ± 70   960 ± 100
PBP235/02-A501P 40 ± 1   250 ± 20 810 ± 40
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